CTCs in Cervix Cancer

Completed

• Conditions: HPV; Cervical Cancer
• Interventions: Diagnostic Test: Blood Assayed for CTCs

• Registration Number: NCT04064515
• Lead Sponsor: NYU Langone Health

Brief Summary

This study is a validation study to confirm the ability of Telomescan OBP-401 to identify CTCs in patients with HPV 16 / 18 associated cervical cancer. CTCs identified will be tested for the presence of the HPV 16 / 18 E6 protein, confirming a cervical cancer origin.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2019-08-20
• Study First Submitted QC: 2019-08-20
• Study First Posted: 2019-08-22
• Study Start: 2020-03-02
• Primary Completion: 2020-04-23
• Study Completion: 2020-04-23
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-04
• Last Update Posted: 2022-08-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 4

Inclusion Criteria

• Able to safely provide 15 ml of blood
• Able to provide informed consent
• Pathologically confirmed invasive cervical cancer
• Proof of serotype HPV 16 or HPV 18 positive within 3 years of the study
• Patients with stages IIA2 to IVB OR recurrent cervical cancer
• For patients with newly diagnosed cervical cancer, they must be enrolled (blood drawn) prior to initiating anti-cancer therapy
• For patients with recurrent cervical cancer, they must be enrolled (blood drawn) prior to initiating a new anti-cancer therapy for progression of disease (based on RECIST 1.1 criteria). Patients who have progressed and are moving to best supportive care are eligible.
• If patients meet criteria 5.1A 5 above, the following criteria must be met:
• At least 21 days have elapsed following treatment with cytotoxic chemotherapy
• At least 14 days have elapsed following treatment with biologic therapy
• At least 14 days have elapsed following radiation therapy

Read More

Exclusion Criteria

• History of any cancer other than cervix cancer within the past five years.
• History of any known germ-line pathogenic mutation (ie BRCA 1 / 2 or Lynch syndrome, but genetic testing is not required)
• Current use of systemic corticosteroids at doses exceeding 10 mg per day of prednisone or its equivalent.
• Active infection including hepatitis B, hepatitis C, HIV.
• Any patient unable to comply with the study criteria.
• Patients taking any anti-inflammatory agents (aspirin, NSAIDs, steroids), within 24 hrs prior to blood draw.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Control	Blood Assayed for CTCs	Participants without a history of cervical cancer or high grade pre-cancer of the cervix
Cervical Cancer	Blood Assayed for CTCs	Participants with advanced or recurrent cervical cancer will provide 15 mL of whole blood. Participants will then be followed prospectively for three years to document oncologic outcome.

Primary Outcome Measures

Name	Time	Method
Effectiveness of OBP-401 to identify CTCs in patients with active HPV 16 / 18 associated cervical cancer compared to non-cancer controls (patients without CIN 2 - 3 or cancer).	3 Years

Secondary Outcome Measures

Name	Time	Method
Presence of HPV 16 or 18 genome in the samples with a positive CTC result, in order to confirm a cervical cancer origin.	3 Years
Recurrence rates in patients stratified by CTC identification	3 Years

Trial Locations

Locations (1)

NYU Langone Health; 🇺🇸 New York, New York, United States